GHK-Cu Monitoring for Young Adults (18 to 29): Lab Work, Safety Checks, and Follow-Up Schedules

What the two human trials measured

A randomized trial of CO2-laser-resurfaced circumoral skin had 13 patients complete post-treatment skin care with or without GHK-Cu; computer analysis and blinded evaluators found no significant difference in redness, wrinkles or overall skin quality, while a patient questionnaire favored GHK-Cu on overall skin quality (P=.04) [2].

A prospective randomized evaluator-blinded trial in venous stasis ulcers had 86 evaluable patients; a 0.4% tripeptide copper complex cream was no different from placebo for ulcer size, while silver sulfadiazine 1% reduced it [1].

A 2026 systematic review that kept 64 records describes the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams; it states that microneedle delivery has not been tested in a single registered, adequately powered human randomized trial [9].

There is no FDA-approved GHK-Cu product or dose [5], and cosmetic strengths are set by manufacturers without FDA review [7].

What the FDA says about GHK-Cu

No FDA-approved drug is known to contain GHK-Cu [5]. It is a different compound from copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [6].

Whether a topical copper peptide product is a cosmetic or a drug depends on its intended use. Claims to treat disease or affect the body's structure or function make it a drug, and cosmetics do not need FDA approval before sale [7].

Non-injectable GHK-Cu sits in category 1 on FDA's interim list for state-licensed pharmacies and physicians, the group under evaluation for the bulk substances list, and FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether to include it; no vote has happened [5][10]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [11].

Injectable GHK-Cu is listed in FDA's 'nominated but withdrawn' table [3]. FDA states: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3]. Injectable GHK-Cu is not FDA-approved [5], and unlike topical products sold as cosmetics, it is not a cosmetic [7].

A copper reference from a different product

Cupric chloride injection is an intravenous copper supplement for total parenteral nutrition; it is not GHK-Cu [8]. Its label lists normal serum copper values of 80 to 163 mcg/dL and says that copper given to patients with Wilson disease may cause increased hepatic accumulation and aggravate underlying hepatocellular degeneration [8]. Those statements belong to that product's label and do not establish a testing schedule for GHK-Cu.